Defining type 2 diabetes remission: KISS goodbye to confusion?
Taheri S
Lancet Diabetes Endocrinol. 2021;S2213-8587(21)00290-4
Leggi
Breaking news
Statin Intolerance and Non-Compliance: An Empiric Approach
Grundy SM, Vega GL
Am J Med. 2021;S0002-9343(21)00644-6
Leggi
Flash glucose monitoring and automated bolus calculation in type 1 diabetes treated with multiple daily insulin injections: a 26 week randomised, controlled, multicentre trial
Secher AL, Pedersen-Bjergaard U, Svendsen OL, et al.
Diabetologia. 2021;64:2713–2724.
Leggi
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial
Del Prato S, Kahn SE, Pavo I, et al.
Lancet. 2021;S0140-6736(21)02188-7
Leggi
FORXIGA (dapagliflozin) 5mg – non deve essere più utilizzato per il trattamento del diabete mellito di tipo 1
29/10/2021
Leggi
Cluster Analysis of Cardiovascular Phenotypes in Patients With Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease: A Potential Approach to Precision Medicine
Sharma A, Zheng Y, Ezekowitz JA, et al.
Diabetes Care. 2021;dc202806.
Leggi
The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials
Lin DSH, Lee JK, Hung CS, Chen WJ
Diabetologia. 2021;64:2676–2686.
Leggi
Prior glucose-lowering medication use and 30-day outcomes among 64,892 veterans with diabetes and covid-19
Wander PL, Lowy E, Beste LA, et al.
Diabetes Care. 2021;dc211351
Leggi
Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial
Jongs N, Greene T, Chertow GM, et al.
Lancet Diabetes Endocrinol. 2021;S2213-8587(21)00243-6.
Leggi